Zetiq completes first arm of cervical cancer study

The goal of the trial was to demonstrate and measure the ability of Zetiq’s technology to accurately diagnose the presence of cervical cancer cells and the stage of the disease, including in early stages of malignancy, in cervical biopsies.

The study reviewed 60 biopsy samples obtained from the archive of Meir MC in Israel which were selected by an unrelated party. The study results demonstrated 100% correlation between the diagnosis based on Zetiq’s technology and diagnosis based upon H&E staining, the current gold standard diagnostic tool used to identify cervical cancer.

The study included both biopsy samples without any abnormal findings as well as biopsy samples from advanced disease stages, including from early premalignant stages of the disease. The company’s technology was able to diagnose the samples by both a color stain of the cancer cells as well as the morphological cell changes.

On the basis of the positive results, Zetiq intends to pursue the development of its diagnostic product for diagnosis of cervical cancer. The second arm of the study, aimed at implementing the technology as a screening survey application to point to potential cases of cervical cancer, is still ongoing.

Adi Elkeles, CEO of Zetiq, said: We are very encouraged by the results of this trial, which provide a novel tool for cancer diagnostics. This important milestone sets the stage for continuing our efforts to develop diagnostic tools for cervical cancer, and opens the door to expanding our efforts to develop diagnostic tools for additional cancer indications.